Plasma cell neoplasms

Rafael Fonseca, Riccardo Valdez

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Plasma cell neoplasms result from the clonal expansion of terminally differentiated B-cells that have the capacity to secrete a monoclonal immunoglobulin (Ig). This chapter will discuss the appropriate use of diagnostic techniques in the diagnosis and assessment of multiple myeloma, monoclonal gammopathy of undetermined significance, smoldering myeloma, plasma cell leukemia and Waldenström macroglobulinemia. Multiple myeloma Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of plasma cells (PC), mostly within the bone marrow (BM). The disease peaks in incidence in the seventh decade of life. While still considered an incurable diagnosis for most patients, patients are surviving longer due to the availability of new treatments. In a subset of patients, mostly those treated with more aggressive interventions such as combinations of novel agents and autologous stem cell transplant (SCT), the disease may be curable. MM is part of a spectrum of disorders characterized by this proliferation of clonal PC which includes monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). In MGUS, patients have a minimal plasmacytosis and the monoclonal PCs cause no harm to the individual; it is usually detected incidentally. Patients with MGUS can go on for years, often decades, without ever having further expansion of the monoclonal PCs. Patients with SMM have a more advanced plasmacytosis, yet have no discernible evidence of end organ damage due to this expansion.

Original languageEnglish (US)
Title of host publicationDiagnostic Techniques in Hematological Malignancies
PublisherCambridge University Press
Pages244-265
Number of pages22
Volume9780521111218
ISBN (Print)9780511760273, 9780521111218
DOIs
StatePublished - Jan 1 2010

Fingerprint

Plasma Cell Neoplasms
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Plasma Cells
Plasma Cell Leukemia
Waldenstrom Macroglobulinemia
Immunoglobulins
B-Lymphocytes
Stem Cells
Bone Marrow
Transplants
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fonseca, R., & Valdez, R. (2010). Plasma cell neoplasms. In Diagnostic Techniques in Hematological Malignancies (Vol. 9780521111218, pp. 244-265). Cambridge University Press. https://doi.org/10.1017/CBO9780511760273.013

Plasma cell neoplasms. / Fonseca, Rafael; Valdez, Riccardo.

Diagnostic Techniques in Hematological Malignancies. Vol. 9780521111218 Cambridge University Press, 2010. p. 244-265.

Research output: Chapter in Book/Report/Conference proceedingChapter

Fonseca, R & Valdez, R 2010, Plasma cell neoplasms. in Diagnostic Techniques in Hematological Malignancies. vol. 9780521111218, Cambridge University Press, pp. 244-265. https://doi.org/10.1017/CBO9780511760273.013
Fonseca R, Valdez R. Plasma cell neoplasms. In Diagnostic Techniques in Hematological Malignancies. Vol. 9780521111218. Cambridge University Press. 2010. p. 244-265 https://doi.org/10.1017/CBO9780511760273.013
Fonseca, Rafael ; Valdez, Riccardo. / Plasma cell neoplasms. Diagnostic Techniques in Hematological Malignancies. Vol. 9780521111218 Cambridge University Press, 2010. pp. 244-265
@inbook{358bb4cd63514643a0ce53b3f69ffa1a,
title = "Plasma cell neoplasms",
abstract = "Introduction Plasma cell neoplasms result from the clonal expansion of terminally differentiated B-cells that have the capacity to secrete a monoclonal immunoglobulin (Ig). This chapter will discuss the appropriate use of diagnostic techniques in the diagnosis and assessment of multiple myeloma, monoclonal gammopathy of undetermined significance, smoldering myeloma, plasma cell leukemia and Waldenstr{\"o}m macroglobulinemia. Multiple myeloma Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of plasma cells (PC), mostly within the bone marrow (BM). The disease peaks in incidence in the seventh decade of life. While still considered an incurable diagnosis for most patients, patients are surviving longer due to the availability of new treatments. In a subset of patients, mostly those treated with more aggressive interventions such as combinations of novel agents and autologous stem cell transplant (SCT), the disease may be curable. MM is part of a spectrum of disorders characterized by this proliferation of clonal PC which includes monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). In MGUS, patients have a minimal plasmacytosis and the monoclonal PCs cause no harm to the individual; it is usually detected incidentally. Patients with MGUS can go on for years, often decades, without ever having further expansion of the monoclonal PCs. Patients with SMM have a more advanced plasmacytosis, yet have no discernible evidence of end organ damage due to this expansion.",
author = "Rafael Fonseca and Riccardo Valdez",
year = "2010",
month = "1",
day = "1",
doi = "10.1017/CBO9780511760273.013",
language = "English (US)",
isbn = "9780511760273",
volume = "9780521111218",
pages = "244--265",
booktitle = "Diagnostic Techniques in Hematological Malignancies",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Plasma cell neoplasms

AU - Fonseca, Rafael

AU - Valdez, Riccardo

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Introduction Plasma cell neoplasms result from the clonal expansion of terminally differentiated B-cells that have the capacity to secrete a monoclonal immunoglobulin (Ig). This chapter will discuss the appropriate use of diagnostic techniques in the diagnosis and assessment of multiple myeloma, monoclonal gammopathy of undetermined significance, smoldering myeloma, plasma cell leukemia and Waldenström macroglobulinemia. Multiple myeloma Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of plasma cells (PC), mostly within the bone marrow (BM). The disease peaks in incidence in the seventh decade of life. While still considered an incurable diagnosis for most patients, patients are surviving longer due to the availability of new treatments. In a subset of patients, mostly those treated with more aggressive interventions such as combinations of novel agents and autologous stem cell transplant (SCT), the disease may be curable. MM is part of a spectrum of disorders characterized by this proliferation of clonal PC which includes monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). In MGUS, patients have a minimal plasmacytosis and the monoclonal PCs cause no harm to the individual; it is usually detected incidentally. Patients with MGUS can go on for years, often decades, without ever having further expansion of the monoclonal PCs. Patients with SMM have a more advanced plasmacytosis, yet have no discernible evidence of end organ damage due to this expansion.

AB - Introduction Plasma cell neoplasms result from the clonal expansion of terminally differentiated B-cells that have the capacity to secrete a monoclonal immunoglobulin (Ig). This chapter will discuss the appropriate use of diagnostic techniques in the diagnosis and assessment of multiple myeloma, monoclonal gammopathy of undetermined significance, smoldering myeloma, plasma cell leukemia and Waldenström macroglobulinemia. Multiple myeloma Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of plasma cells (PC), mostly within the bone marrow (BM). The disease peaks in incidence in the seventh decade of life. While still considered an incurable diagnosis for most patients, patients are surviving longer due to the availability of new treatments. In a subset of patients, mostly those treated with more aggressive interventions such as combinations of novel agents and autologous stem cell transplant (SCT), the disease may be curable. MM is part of a spectrum of disorders characterized by this proliferation of clonal PC which includes monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). In MGUS, patients have a minimal plasmacytosis and the monoclonal PCs cause no harm to the individual; it is usually detected incidentally. Patients with MGUS can go on for years, often decades, without ever having further expansion of the monoclonal PCs. Patients with SMM have a more advanced plasmacytosis, yet have no discernible evidence of end organ damage due to this expansion.

UR - http://www.scopus.com/inward/record.url?scp=84926995469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926995469&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511760273.013

DO - 10.1017/CBO9780511760273.013

M3 - Chapter

AN - SCOPUS:84926995469

SN - 9780511760273

SN - 9780521111218

VL - 9780521111218

SP - 244

EP - 265

BT - Diagnostic Techniques in Hematological Malignancies

PB - Cambridge University Press

ER -